Cargando…
Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage
Mesenchymal stem cells (MSC) preferentially migrate to damaged tissues and, due to their immunomodulatory and trophic properties, contribute to tissue repair. Although MSC express molecules, such as membrane cofactor protein (CD46), complement decay-accelerating factor (CD55), and protectin (CD59),...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608620/ https://www.ncbi.nlm.nih.gov/pubmed/23555976 http://dx.doi.org/10.1371/journal.pone.0060461 |
_version_ | 1782264257287553024 |
---|---|
author | Soland, Melisa A. Bego, Mariana Colletti, Evan Zanjani, Esmail D. St. Jeor, Stephen Porada, Christopher D. Almeida-Porada, Graça |
author_facet | Soland, Melisa A. Bego, Mariana Colletti, Evan Zanjani, Esmail D. St. Jeor, Stephen Porada, Christopher D. Almeida-Porada, Graça |
author_sort | Soland, Melisa A. |
collection | PubMed |
description | Mesenchymal stem cells (MSC) preferentially migrate to damaged tissues and, due to their immunomodulatory and trophic properties, contribute to tissue repair. Although MSC express molecules, such as membrane cofactor protein (CD46), complement decay-accelerating factor (CD55), and protectin (CD59), which confer protection from complement-mediated lysis, MSC are recruited and activated by anaphylatoxins after transplantation, potentially causing MSC death and limiting therapeutic benefit. We have previously demonstrated that transduction of MSC with a retrovirus encoding HCMV-US proteins resulted in higher levels of MSC engraftment due to decreased HLA-I expression. Here, we investigate whether engineering MSC to express US2 (MSC-US2), US3 (MSC-US3), US6 (MSC-US6), or US11 (MSC-US11) HCMV proteins can alter complement recognition, thereby better protecting MSC from complement attack and lysis. HCMV-US proteins increased MSC CD59 expression at different levels as determined by flow cytometric evaluation of the median fluorescence intensity ratio (MFI). A significant increase in CD59 expression was seen in MSC-US2, MSC-US3, and MSC-US6, but not in MSC-US11. Only MSC-US2 displayed increased expression of CD46, while US2 and US3 proteins were both able to augment the percentage of MSC expressing this molecule. Regardless of the HCMV protein expressed, none changed CD55 MFI; however, expression of US6, US11, and US2 each increased the percentage of MSC that were positive for this molecule. Because US2 protein was the most efficient in up-regulating all three complement regulatory proteins, we used a functional complement-mediated cytotoxicity assay to investigate whether MSC-US2 were protected from complement-mediated lysis. We demonstrated that over-expression of the US2 protein reduced complement lysis by 59.10±12.89% when compared to untransduced MSC. This is the first report, to our knowledge, describing a role of HCMV-US proteins in complement evasion, and our data shows that over-expression of US2 protein on MSC could serve as a strategy to protect these cells from complement lysis. |
format | Online Article Text |
id | pubmed-3608620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36086202013-04-03 Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage Soland, Melisa A. Bego, Mariana Colletti, Evan Zanjani, Esmail D. St. Jeor, Stephen Porada, Christopher D. Almeida-Porada, Graça PLoS One Research Article Mesenchymal stem cells (MSC) preferentially migrate to damaged tissues and, due to their immunomodulatory and trophic properties, contribute to tissue repair. Although MSC express molecules, such as membrane cofactor protein (CD46), complement decay-accelerating factor (CD55), and protectin (CD59), which confer protection from complement-mediated lysis, MSC are recruited and activated by anaphylatoxins after transplantation, potentially causing MSC death and limiting therapeutic benefit. We have previously demonstrated that transduction of MSC with a retrovirus encoding HCMV-US proteins resulted in higher levels of MSC engraftment due to decreased HLA-I expression. Here, we investigate whether engineering MSC to express US2 (MSC-US2), US3 (MSC-US3), US6 (MSC-US6), or US11 (MSC-US11) HCMV proteins can alter complement recognition, thereby better protecting MSC from complement attack and lysis. HCMV-US proteins increased MSC CD59 expression at different levels as determined by flow cytometric evaluation of the median fluorescence intensity ratio (MFI). A significant increase in CD59 expression was seen in MSC-US2, MSC-US3, and MSC-US6, but not in MSC-US11. Only MSC-US2 displayed increased expression of CD46, while US2 and US3 proteins were both able to augment the percentage of MSC expressing this molecule. Regardless of the HCMV protein expressed, none changed CD55 MFI; however, expression of US6, US11, and US2 each increased the percentage of MSC that were positive for this molecule. Because US2 protein was the most efficient in up-regulating all three complement regulatory proteins, we used a functional complement-mediated cytotoxicity assay to investigate whether MSC-US2 were protected from complement-mediated lysis. We demonstrated that over-expression of the US2 protein reduced complement lysis by 59.10±12.89% when compared to untransduced MSC. This is the first report, to our knowledge, describing a role of HCMV-US proteins in complement evasion, and our data shows that over-expression of US2 protein on MSC could serve as a strategy to protect these cells from complement lysis. Public Library of Science 2013-03-26 /pmc/articles/PMC3608620/ /pubmed/23555976 http://dx.doi.org/10.1371/journal.pone.0060461 Text en © 2013 Soland et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Soland, Melisa A. Bego, Mariana Colletti, Evan Zanjani, Esmail D. St. Jeor, Stephen Porada, Christopher D. Almeida-Porada, Graça Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage |
title | Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage |
title_full | Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage |
title_fullStr | Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage |
title_full_unstemmed | Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage |
title_short | Mesenchymal Stem Cells Engineered to Inhibit Complement-Mediated Damage |
title_sort | mesenchymal stem cells engineered to inhibit complement-mediated damage |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608620/ https://www.ncbi.nlm.nih.gov/pubmed/23555976 http://dx.doi.org/10.1371/journal.pone.0060461 |
work_keys_str_mv | AT solandmelisaa mesenchymalstemcellsengineeredtoinhibitcomplementmediateddamage AT begomariana mesenchymalstemcellsengineeredtoinhibitcomplementmediateddamage AT collettievan mesenchymalstemcellsengineeredtoinhibitcomplementmediateddamage AT zanjaniesmaild mesenchymalstemcellsengineeredtoinhibitcomplementmediateddamage AT stjeorstephen mesenchymalstemcellsengineeredtoinhibitcomplementmediateddamage AT poradachristopherd mesenchymalstemcellsengineeredtoinhibitcomplementmediateddamage AT almeidaporadagraca mesenchymalstemcellsengineeredtoinhibitcomplementmediateddamage |